Navigation Links
Enteris BioPharma and Nordic BioScience's KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris' Proprietary Oral Drug Delivery and Manufacturing Platform

BOONTON, N.J., Sept. 30, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, and KeyBioScience, a wholly-owned subsidiary of Nordic Bioscience, today announced a strategic licensing agreement for Enteris' oral drug delivery and recombinant manufacturing technologies to advance the development of KeyBioScience's recently acquired family of proprietary metabolic peptides for various indications, including the treatment of Type 2 diabetes, obesity and other inflammatory conditions with high unmet medical and socioeconomic needs. 

The licensing agreement with KeyBioScience marks the first significant revenue-generating partnership for Enteris since its inception in April 2013, and is representative of the company's broader "Feasibility-to-Licensing" strategy involving Peptelligence™, its peptide and small molecule oral drug delivery platform.  For KeyBioScience, the licensing agreement signals its transition to a clinical stage company following its formation by Nordic Bioscience. 

Under the terms of the agreement, Enteris will license to KeyBioScience its oral drug delivery and recombinant manufacturing technologies, as well as become the exclusive provider of pre-clinical and clinical trial API and solid dosage form finished product and will receive both fee-for-service revenues and royalties based on net sales of the developed products. 

Brian Zietsman, President and CFO of Enteris BioPharma, commented, "I cannot overemphasize the significance of this licensing agreement for Enteris and the excitement we share with Nordic Bioscience and its wholly-owned subsidiary KeyBioScience, especially given the tremendous potential therapeutic benefit and multi-billion dollar commercial potential of the compounds under development.  Importantly, for Enteris, this licensing agreement showcases our unique ability to partner with global pharmaceutical companies to develop and progress orally delivered peptide and small molecule drugs utilizing our Peptelligence™ platform.  Looking ahead, we are focused on expanding our portfolio of 'feasibility-to-licensing' agreements with both established and emerging biopharmaceutical companies that recognize the market opportunity afforded by formulating peptides and small molecules for oral drug delivery."

Dr. Morten Asser Karsdal, Professor and CEO of KeyBioScience, remarked, "Advancing the licensed peptides to the clinic is the first step in what we believe will ultimately become a new paradigm for peptide-based therapeutics and the treatment of metabolic disease.  Our ability to both apply and leverage Enteris' Peptelligence™ platform will be critical to our success as we progress into advanced-stage clinical trials and potential commercialization."

Peptelligence™ is a clinically proven formulation technology that enables the oral delivery of BCS class II, III and IV peptide and small molecule compounds in a proprietary enteric-coated tablet formulation.  Peptelligence™ has demonstrated a unique track record of clinical success across a range of compounds and therapeutic indications, including a positive outcome pivotal Phase 3 trial.

About Nordic Bioscience
Nordic Bioscience discovers and develops innovative medical treatments to help millions of people around the world suffering from serious, chronic, degenerative diseases such as osteoporosis and osteoarthritis, as well as metabolic disorders such as Type 2 diabetes.  Since its incorporation in 1989, Nordic Bioscience has strived to revolutionize the in vitro diagnostics field, allowing the company to discover and design innovative drug development programs, in part through highly focused drug repositioning by serological measurements. The in-house developed biomarker platform, a unique measure of protein fingerprints, positions Nordic Bioscience as the leading scientific company within biomarker development.

About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. 
Peptelligence™ has demonstrated a track record of clinical success across a range of compounds and therapeutic indications and has also been the subject of numerous feasibility studies and active development programs, several of which are in advanced stages of clinical development. For more information on Enteris BioPharma and Peptelligence™, please visit

For Enteris BioPharma:          

Media Contacts:

Arlyn Peguero


Jason Rando / Claire Sojda

Tiberend Strategic Advisors, Inc.


SOURCE Enteris BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
11. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):